新绿原酸抑制血管生成的研究

目的 考察新绿原酸(5-caffeoylquinic acid, 5-CQA)对血管生成的影响。方法 应用人脐内皮细胞(HUVEC)、大鼠动脉环模型和转基因血管荧光斑马鱼模型考察5-CQA对血管生成的抑制作用。同时建立肿瘤细胞斑马鱼移植瘤模型，考察5-CQA对肠下静脉(subintestinal vein, SIV)生成的作用。结果 5-CQA在320μmol·L^-1及以下浓度对HUVEC的增殖无明显影响，5-CQA能够抑制HUVEC体外迁移及细胞中VEGF、bFGF mRNA的表达；与对照组比较，56和112μmol·L^-1的5-CQA具有显著抑制大鼠动脉环微血管生成的作用(P<0.05);在斑马鱼血管荧光模型中56和112μmol·L^-1的5-CQA具有显著抑制24 h斑马鱼节间血管(intersegmental vessel, ISV)生成的作用；同时5-CQA对斑马鱼移植瘤的肠下静脉生成具有明显抑制作用(P<0.05)。结论 5-CQA具有抑制血管生成的作用，其作用机制与抑制VEGFR2受体的表达有关...     

革皮氏海参皂苷抑制血管新生作用

目的以革皮氏海参中分离得到的三萜皂苷ho-lothurin A1(HA)和24-dehydroechinoside A(DA)为研究对象,比较研究其抗血管新生的作用。方法采用MTT法和AO/EB染色法检测不同剂量HA和DA对人脐静脉内皮细胞(HUVEC)增殖和凋亡的影响;采用小管形成实验观察HA和DA对HUVEC分化形成小管能力的影响;细胞黏附实验比较研究HA和DA对HUVEC与肝癌细胞HepG2的黏附能力的影响;鸡胚绒毛尿囊膜(CAM)血管新生模型,观察HA和DA抑制CAM血管新生的情况。结果 HA和DA均具有抑制HUVEC增殖的活性(48 h的IC50值分别为4.80、3.82μmol.L-1),并能促进内皮细胞的凋亡;在体外能抑制内皮细胞小管形成,可抑制HUVEC与HepG2细胞间(P<0.01)的黏附,能使CAM新生血管明显减少,其中DA抑制血管新生活性优于HA。结论海参皂苷HA和DA具有抑制血管新生的作用,其活性与其结构相关。     

西妥昔单抗抑制血管生成的实验研究

目的 探讨西妥昔单抗(C225)对体内、外血管生成的抑制作用.方法 用人脐静脉内皮细胞(HUVEC)原代培养模型,分别采用四甲基偶氮唑盐(MTT)法、Transwell小室趋化实验、体外小管形成实验及流式细胞术,观察C225在体外对HUVEC增殖、迁移、小管形成和凋亡的影响;利用鸡胚绒毛尿囊膜(CAM)模型,观察C225对CAM新生血管的抑制作用.结果 0.0625～2.0000μg/ml的C225作用HUVEC 48 h,细胞增殖抑制牢为12.34%～25.26%;体外迁移及小管形成实验显示,0.0625～1.0000 μg/ml C225的HUVEC迁移抑制率为15.51%～48.68%,HUVEC小管形成抑制率为22.91%～44.71%;0.25 μg/ml和1.00 μg/ml的C225诱导HUVEC细胞凋亡率分别为33.20%和35.05%.体内CAM试验表明,0.0625～1.0000 μg/ml的C225对新生血管抑制率为20.39%～36.18%.结论 C225在体内、外具有血管生成作用.     

λ-卡拉胶寡糖体外对血管生成的抑制作用

为探讨λ-卡拉胶寡糖体外对血管生成的抑制作用,采用鸡胚尿囊膜模型(CAM)观察λ-卡拉胶寡糖对CAM血管发育的抑制,发现该寡糖可明显抑制CAM微血管生成,在200 μg·egg-1时,抑制率达54.90%.随后采用MTT法测定λ-卡拉胶寡糖对人脐静脉内皮细胞(HUVEC)增殖的影响,发现该寡糖的细胞毒作用在不同的细胞间具有选择性,对HUVEC的抑制最强,高浓度时(1 mg·mL-1)能明显抑制其增殖,但低浓度(＜250 μg·mL-1)对细胞几乎无毒.对寡糖的细胞迁移和侵袭抑制作用进行检测,并测定其对HUVEC表达基质金属蛋白酶-2(MMP-2)的影响.结果表明,λ-卡拉胶寡糖能有效减缓HUVEC的迁移、侵袭能力,并具有抑制HUVEC中MMP-2表达的作用.该研究说明λ-卡拉胶寡糖通过抑制内皮细胞的增殖、细胞侵袭和迁移达到血管生成抑制的作用.     

靶向内皮细胞α7受体的新化合物对鸡胚绒毛尿囊膜血管生成的影响

目的 :研究靶向内皮细胞α7受体的新化合物对鸡胚绒毛尿囊膜 (CAM)血管新生的影响。方法 :应用鸡胚绒毛尿囊膜模型 ,通过计数血管的分支点数 ,观察 16种靶向内皮细胞α7受体的新化合物对于在体血管新生的影响。结果与结论 :化合物 13、14在 1～ 10 0 μmol·L-1浓度范围内 ,既没有促进血管新生的作用 ,也没有抑制血管新生的作用 ,与生理盐水组相比无显著差异 ,而在浓度为 10 0 0 μmol·L-1时 ,对CAM的血管新生有促进作用。化合物 5在浓度为 10 0和 10 0 0 μmol·L-1有抑制血管新生的作用 ,而在浓度为 1和 10 μmol·L-1时 ,则对血管新生没有影响     

蝎毒多肽提取物抗肿瘤血管生成作用的实验研究

目的探讨东亚钳蝎蝎毒的多肽提取物PESV的抗血管生成活性和对肿瘤生长的抑制作用。方法①用不同浓度的PESV(4～20mg·L-1)作用于人脐静脉内皮细胞(HUVEC),采用BrdU参入的ELISA法观察HUVEC增殖活性和凋亡水平变化,流式细胞术检测凋亡细胞比例,免疫组化法检测Bal和Bax表达。②观察PESV对鸡胚尿囊膜(CAM)新生血管生成的影响。③皮下注射PESV(0.3mg·kg-1),观察对S180肉瘤和H22肝癌荷瘤小鼠肿瘤生长、肿瘤血管生成和血管生成因子(VEGF和bFGF)表达的影响。结果①体外实验显示,PESV在8～20mg·L-1范围明显抑制HUVEC的增殖活性(与对照组比较,P<0.01),而对乳腺癌细胞MDAMB231的增殖无影响;PESV作用后HUVEC凋亡细胞比例较对照组增加,P<0.05,Bax表达增加;Bcl2表达降低。②0.5mg/CAM和0.8mg/CAM的PESV能明显抑制CAM新生血管的形成。③体内实验显示PESV能明显抑制小鼠S180肉瘤和H22肝癌的肿瘤生长和血管生成水平,并降低肿瘤组织内血管生成相关因子VEGF和bFGF的表达。结论PESV具有良好的体内和体外抗肿瘤血管生成活性,并籍此抑制肿瘤的生长。     

λ-卡拉胶禀糖体外对血管生成的抑制作用

为探讨λ-卡拉胶寡糖体外对血管生成的抑制作用，采用鸡胚尿囊膜模型（CAM）观察λ-卡拉胶寡糖对CAM血管发育的抑制，发现该寡糖可明显抑制CAM微血管生成，在200μg·egg^-1时，抑制率达54．90％。随后采用MTT法测定λ-卡拉胶寡糖对人脐静脉内皮细胞（HUVEC）增殖的影响，发现该寡糖的细胞毒作用在不同的细胞间具有选择性．对HUVEC的抑制最强，高浓度时（1mg·mL^-1）能明显抑制其增殖．但低浓度（〈250μg·mL^-1）对细胞几乎无毒。对寡糖的细胞迁移和侵袭抑制作用进行检测，并测定其对HUVEC表达基质金属蛋白酶-2（MMP-2）的影响。结果表明，λ-卡拉胶寡糖能有效减缓HUVEC的迁移、侵袭能力，并具有抑制HUVEC中MMP-2表达的作用。该研究说明λ-卡拉胶寡糖通过抑制内皮细胞的增殖、细胞侵袭和迁移达到血管生成抑制的作用。     

岩藻糖基化海参硫酸软骨素抑制肿瘤血管新生作用的研究

目的从美国肉参(Isostichopus badionotus)中分离纯化岩藻糖基化海参硫酸软骨素(sea cucumber chondroitin sulfate,SC-CHS),体外研究其对肿瘤诱导血管生成的抑制作用。方法采用MTT法检测SC-CHS对95D细胞增殖活性的影响;小管形成实验研究SC-CHS对脐静脉内皮细胞(HUVEC)小管形成能力的抑制作用;采用鸡胚尿囊膜(CAM)新生血管模型,研究其对血管生成的影响;通过RT-PCR和WesternBlot法检测其对肿瘤诱导血管生成相关因子缺氧诱导因子(hypoxia inducible factor-1α,Hif-1α)和血管内皮生长因子(vascular endothelial growth factor,VEGF)mRNA和蛋白的表达。结果结果显示SC-CHS能显著抑制95D细胞的增殖,能抑制HUVEC的小管形成作用和CAM血管新生。RT-PCR和Western Blot检测结果表明,高剂量SC-CHS能显著降低95D细胞中Hif-1α和VEGF mRNA的表达,减少VEGF蛋白的合成。结论SC-CHS体外能显著抑制肿瘤血管生成,这可能是通过影响肿瘤细胞中VEGF的合成发挥作用。     

氧化吲哚类化合物Z24的体内抑瘤活性及其血管生成抑制作用(英文)

目的　从抗血管生成活性的角度 ,寻找新的抗肿瘤药物 ,研究Z2 4的体内抑瘤活性及其对血管内皮细胞的选择性抑制作用。方法　MTT法检测不同浓度的Z2 4作用 72h时对人肝癌细胞系BEL 74 0 2及正常人胚肺二倍体细胞 2BS的生长抑制作用 ,并从浓度 抑制率曲线求出IC50 ;台盼蓝拒染计数法检测不同浓度的Z2 4作用 72h时对人脐静脉内皮细胞 (HUVEC)的生长抑制作用 ,从浓度 抑制率曲线求出IC50 ;小鼠S180 ,H2 2和裸小鼠皮下移植性人肝癌BEL 74 0 2模型研究Z2 4的体内抑瘤作用。鸡胚尿囊膜 (CAM )血管生成模型检测Z2 4的血管生成抑制活性。结果　MTT法测得Z2 4对BEL 74 0 2生长抑制作用的IC50 为 10 6 μmol·L- 1,对 2BS生长抑制作用的IC50 为 116 μmol·L- 1。台盼蓝拒染计数法测得Z2 4对HUVEC生长抑制作用的IC50 为 6 .4 4μmol·L- 1。Z2 4可明显抑制鸡CAM新生血管的形成Z2 4 10 0mg·kg- 1可使S180 ,H2 2和裸小鼠人肝癌BEL 74 0 2模型的肿瘤重量较对照组分别下降 5 2 .5 %(n =10 ,P <0 .0 1) ,4 1.5 % (n =10 ,P <0 .0 1)和5 3.4 % (n =6 ,P <0 .0 1)。Z2 4可显著抑制CAM的血管生成。结论　Z2 4对多种肿瘤动物模型均具有显著的体内抑瘤活性 ,对血管内皮细胞有选择性抑制作用 ,并明显抑制CAM新生血管的生成?     

新藤黄酸干预肺腺癌血管生成的细胞学研究

目的 通过对人脐静脉内皮细胞HUVEC和人肺腺癌A549的培养,检测含新藤黄酸(GNA)条件培养基对血管内皮细胞存活率、成管和生长的影响.方法 采用甲基噻唑基四唑(MTT)法和平板克隆实验法研究GNA对HUVEC存活率和克隆形成率的影响;应用薄层胶原建立血管内皮细胞的二维培养模型,观察GN A对于血管内皮细胞成管现象的影响;采用细胞划痕愈合和小室迁移实验考察GNA对HUVEC的迁移能力影响;Westernblot检测血管内皮生长因子(VEGF)和缺氧诱导因子(HIF-1α)蛋白的表达.结果 MTT检测结果显示,HUVEC细胞存活率和克隆形成率随GNA剂量增加而降低.GNA可抑制HUVEC细胞的迁移.还可抑制HUVEC管腔样结构形成.此外,GNA可下调HUVEC中VEGF和HIF-1α蛋白的表达.结论GNA可在体外抑制血管生成,其作用机制可能与抑制肿瘤细胞分泌的HIF-1α和VEGF有关.     

槲皮素抑制血管生成作用的实验研究

目的　研究槲皮素 (Quercetin)对血管生成和培养的人脐静脉内皮细胞 (HUVEC)的影响。方法　采用生长因子 (血管内皮细胞生长因子VEGF、碱性成纤维细胞生长因子bFGF)诱导的鸡胚绒毛尿囊膜 (CAM)血管增生模型观察槲皮素对血管生成的影响 ;利用培养的HUVEC ,用MTT法观察槲皮素抑制内皮细胞增殖的作用 ;流式细胞仪观察槲皮素对HUVEC细胞周期的影响。结果　槲皮素 (0 1、0 0 5和 0 0 2 5mmol·L-1)能明显抑制VEGF诱导的CAM小血管生成 ;槲皮素 (0 1和 0 0 5mmol·L-1)能明显抑制bFGF诱导的CAM小血管生成 ;槲皮素 (2 4 0、12 0 μmol·L-1和 6 0 μmol·L-1)对内皮细胞增殖有抑制作用 ,抑制率分别为 6 7 0 %、5 8 1%和39 7% ;槲皮素 (2 4 0、12 0 μmol·L-1)能显著导致HUVEC的S、G2 期阻滞。结论　槲皮素能抑制VEGF和bFGF诱导的血管生成 ,且对内皮细胞增殖具有抑制作用。     

紫杉醇对兔血管内皮和平滑肌细胞增生影响的差异及意义

目的探讨紫杉醇对兔血管内皮和平滑肌增生影响的差异及意义.方法将兔血管平滑肌细胞接种于共培养体系上室、内皮细胞接种于下室建立体外内膜修复模型,观察紫杉醇对兔血管平滑肌和内皮细胞3H-TdR掺入、细胞计数和迁移率的影响,用直线回归法计算紫杉醇对平滑肌和内皮细胞增生迁移的半数有效抑制浓度IC50.结果在1 nmol·L-1～1 μmol·L-1之间,紫杉醇呈浓度依赖地抑制平滑肌细胞3H-TdR掺入、细胞计数和迁移(n=6, P＜0.01).在10 nmol·L-1～1 μmol·L-1之间,紫杉醇呈浓度依赖地抑制内皮细胞3H-TdR掺入、细胞计数和迁移(n=6, P＜0.01).1 nmol·L-1紫杉醇对内皮细胞3H-TdR掺入和细胞计数有抑制倾向,但与对照组相比无统计学差异.而1 nmol·L-1的紫杉醇却已显著抑制内皮细胞迁移(n=6, P＜0.01).紫杉醇对兔血管平滑肌细胞增生、迁移抑制的IC50分别为 10.09±0.47、9.16±0.54 nmol·L-1,对内皮细胞增生、迁移抑制的IC50分别为 19.05±0.35、5.37±0.51 nmol·L-1.10 nmol·L-1紫杉醇作用 20 min 在观察时间内能持续抑制融合内皮组平滑肌增生,而对数内皮组平滑肌增殖在10 d时明显高于对照组.结论紫杉醇在抑制兔血管平滑肌细胞增生的同时也抑制内皮增生,紫杉醇干预后平滑肌细胞增生延迟与内皮细胞再生延迟密切相关.     

Prevention of FGF-2-induced angiogenesis by scopoletin, a coumarin compound isolated from Erycibe obtusifolia Benth, and its mechanism of action

Previous work in our laboratory has shown that scopoletin, one of the main bioactive constituents of Erycibe obtusifolia Benth stems, exerts anti-arthritic activity in vivo partly by preventing synovial angiogenesis. The present study was performed to further investigate the anti-angiogenic potential of scopoletin, focusing on the mechanisms of action in vitro. In the aortic ring sprouting assay, scopoletin (10, 30 and 100 μM) significantly inhibited the growth of endothelial sprouts in a concentration-dependent manner. As to human umbilical vein endothelial cells (HUVECs), scopoletin could inhibit their proliferation, migration and tubule formation induced by FGF-2, especially the proliferation. It also remarkably decreased the expression of VEGF at mRNA and protein levels, and the phosphorylations of IKKα and IκB but not Akt, as well as the degradation of IκB caused by FGF-2 in HUVECs. These findings suggest that scopoletin is substantially able to attenuate FGF-2-induced angiogenesis, and it might act by directly preventing the stimulation action of FGF-2 and by indirectly decreasing the production of VEGF. Scopoletin down-regulated the VEGF expression through NF-κB rather than PI-3K/Akt signaling pathway.     

Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways

Our previous studies revealed that scopoletin, the main bioactive constituent of Erycibe obtusifolia Benth stems, exerted anti-arthritic activity in vivo partly by preventing synovial angiogenesis. Herein we further investigated the anti-angiogenic potential and related mechanisms of this coumarin compound in vivo and in vitro. On chick chorioallantoic membrane (CAM) model, scopoletin (10, 30, 100 nmol/egg) dose-dependently reduced the blood vessels that were quantified by counting the number of blood vessel branch points. In vitro, scopoletin at concentrations above 30 microM obviously inhibited the VEGF-induced tube formation, proliferation and migration of human umbilical vein endothelial cells (HUVECs). Furthermore, scopoletin was shown to block VEGF-induced autophosphorylation of VEGFR2 but not VEGFR1, and down-regulate the following activation of ERK1/2, p38 MAPK and endothelial nitric oxide synthase (eNOS) as well as the production of nitric oxide (NO) in HUVECs. In sum, our findings further support that scopoletin is a candidate of angiogenesis inhibitors, and it functions by interrupting the autophosphorylation of VEGF receptor 2 (VEGFR2) and the downstream signaling pathways.     

An indirubin derivative, E804, exhibits potent angiosuppressive activity

Angiogenesis, the development of neovessels from pre-existing vessels, is obligatory for solid tumors survival, growth, invasion, and metastasis. Many anti-angiogenic agents are small molecules originated from natural sources. Recently, angiosuppressive effects of indirubin and its derivatives, the active components in indigo-producing herbs, have been shown to possess anti-viral and anti-inflammatory potentials. In this study, we identified another indirubin derivative, indirubin-3'-(2,3 dihydroxypropyl)-oximether (E804), could exhibit potent angiosuppressive effects. In vitro study showed that E804 could significantly inhibit human umbilical vein endothelial cells proliferation, migration, and tube formation in a concentration-dependent manner (0.4-40 μM); at the concentration of 1 μmol or above, angiosuppressive potency of E804 was found to be more significant than indirubin-3'-oxime. Using in vivo Matrigel plug model and directed-in vivo-angiogenesis-assay (DIVAA), E804 was shown more effective to attenuate the VEGF/bFGF-induced neovessel formation. The hemoglobin content and the invaded endothelial cells in the implants were also greatly reduced. Results from the aortic ring assay indicated E804 (4 μM) could completely suppress ex vivo sprouting of endothelial cells from the rat aorta fragments; with concomitant reduction of gelatinolytic activities of matrix metalloproteinase-2 and -9. E804 also concentration-dependently (0.04-10 μM) inhibited the subintestinal vessels formation in zebrafish embryos. This study provides the first evidence that E804, a novel indirubin derivative, could more effectively inhibit angiogenesis. With the improved anti-angiogenic potency when compared with indirubin-3'oxime, E804 would be a new potential candidate in the treatment of angiogenesis-dependent diseases.     

Trans-3,4,5,4′-tetramethoxystilbene,a resveratrol analog,potently inhibits angiogenesis in vitro and in vivo

Aim:

Trans-3,4,5,4′-tetramethoxystilbene (DMU-212) has shown strong antiproliferative activities against a variety of cancer cells. The aim of this study was to investigate the anti-angiogenic effects of DMU-212 in vitro and in vivo.

Methods:

Human umbilical vein endothelial cells (HUVECs) were used in this study. Cell viability was studied with MTT assay, and cell apoptosis was evaluated using TUNEL assay and morphological observation. The expression of the related genes and proteins was analyzed with qRT-PCR and Western blot, respectively. Angiogenesis of HUVECs were studied using cell migration and capillary-like tube formation assays in vitro, and mouse Matrigel plug assay and chick chorioallantoic membrane (CAM) assay in vivo. The tyrosine kinase activities of VEGFR1 and VEGFR2 were measured using commercial kits.

Results:

DMU-212 (5–80 μmol/L) significantly inhibited VEGF-stimulated proliferation of HUVECs (IC₅₀ value was approximately 20 μmol/L), and induced apoptosis. Furthermore, DMU-212 concentration-dependently inhibited VEGF-induced migration of HUVECs and capillary-like structure formation in vitro. DMU-212 also inhibited VEGF-induced generation of new vasculature in Matrigel plugs in vivo with significantly decreased area of infiltrating CD31-positive endothelial cells, and inhibited newly formed microvessels in chick CAMs. Moreover, DMU-212 concentration-dependently suppressed VEGF-induced phosphorylation of VEGFR2, and inhibited phosphorylation of multiple downstream signaling components in the VEGFR2 pathway, including c-Src, FAK, Erk1/2, Akt, mTOR, and p70S6K in HUVECs. DMU-212 had no effect on VEGF-induced phosphorylation of VEGFR1.

Conclusion:

DMU-212 is a potent inhibitor of angiogenesis that exerts anti-angiogenic activity at least in part through the VEGFR2 signaling pathway.     

JS‐K has potent anti‐angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo

Objectives Glutathione S‐transferases (GSTs) play an important role in multidrug resistance and are upregulated in multiple cancers. We have designed a prodrug class that releases nitric oxide on metabolism by GST. O²‐(2,4‐Dinitrophenyl) 1‐[(4‐ethoxycarbonyl)piperazin‐1‐yl]diazen‐1‐ium‐1,2‐diolate (JS‐K, a member of this class) has potent antineoplastic activity. Methods We studied the effect of JS‐K on angiogenesis in human umbilical vein endothelial cells (HUVECs), OPM1 multiple myeloma cells, chick aortic rings and in mice. Key findings JS‐K inhibited the proliferation of HUVECs with a 50% inhibitory concentration (IC50) of 0.432, 0.466 and 0.505 μm at 24, 48 and 72 h, respectively. In the cord formation assay, JS‐K led to a decrease in the number of cord junctions and cord length with an IC50 of 0.637 and 0.696 μm , respectively. JS‐K inhibited cell migration at 5 h using VEGF as a chemoattractant. Migration inhibition occurred with an IC50 of 0.493 μm . In the chick aortic ring assay using VEGF or FGF‐2 for vessel growth stimulation, 0.5 μm JS‐K completely inhibited vessel growth. JS‐K inhibited tumour angiogenesis in vivo in NIH III mice implanted subcutaneously with OPM1 multiple myeloma cells. Conclusions JS‐K is a potent inhibitor of angiogenesis in vitro and tumour vessel growth in vivo. As such, it establishes a new class of antineoplastic agent that targets the malignant cells directly as well as their microenvironment.     

PI3K/Akt抑制剂CCT128930抑制人脐静脉血管内皮细胞增殖与血管生成的实验研究

目的探讨一类新的PI3K/Akt抑制剂CCT128930对人脐静脉血管内皮细胞(HUVEC)增殖与血管生成的影响。方法采用MTT法检测CCT128930对HUVEC存活的影响;流式细胞术分析细胞周期变化;AnnexinⅤ-FITC试剂盒检测细胞凋亡;体外小管形成实验观察CCT128930对HUVEC体外小管形成的影响;免疫印迹法检测蛋白表达水平。结果CCT128930可通过阻滞细胞于G1期而抑制HUVEC的增殖,且抑制作用呈剂量依赖性,但对HUVEC的凋亡无影响;HUVEC经CCT128930处理后,体外小管形成能力受到明显抑制;低浓度的CCT128930抑制内皮细胞中VEGF的表达,但对Akt的磷酸化水平无影响。结论 CCT128930能够抑制HUVEC的增殖与血管生成,其抑制血管生成活性可能与其调控VEGF的表达水平相关。     

5种他汀类药物对鸡胚绒毛尿囊膜血管新生的影响

目的:观察5种他汀类药物对鸡胚绒毛尿囊膜(CAM)血管新生的影响,探讨他汀类药物是否具有独立于血脂调节作用以外的促进血管新生作用。方法:制备CAM模型,将不同浓度他汀类药物、重组牛碱性成纤维细胞生长因子和生理盐水分别通过载体加到CAM上,观察CAM特异性血管生长情况及血管数目变化。结果:不同浓度辛伐他汀(0.02,0.1,0.5,2.5,12.5μmol.L-1)中,当辛伐他汀浓度为0.1μmol.L-1时,CAM血管生成数量明显高于生理盐水对照组(P<0.05),与阳性对照组比较无统计学意义(P>0.05);而不同他汀类药物,即瑞舒伐他汀组(0.025μmol.L-1)、阿托伐他汀组(0.05μmol.L-1)、普伐他汀组(0.2μmol.L-1)、氟伐他汀组(0.4μmol.L-1),CAM血管生成数均明显高于生理盐水组(P<0.05),与阳性对照组比较无统计学意义(P>0.05)。结论:常用5种他汀类药物均有促进CAM血管新生作用;不同浓度辛伐他汀对CAM的作用不同。提示他汀类药物促进血管新生的作用可能与药物剂量有关。